Intensive care management of acute liver failure

Current Opinion in Critical Care

Volumn 14, Issue 2, 2008, Pages 179-188

  Auzinger, Georg ^a   Wendon, Julia ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Acute liver failure; HLA DR expression; Intracranial hypertension; Systemic inflammatory response syndrome

Indexed keywords

ACETYLCYSTEINE; ADRENALIN; AMMONIA; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BARBITURIC ACID DERIVATIVE; CEPHALOSPORIN; CHELATING AGENT; FENTANYL; GLUCOSE; GLUTAMINE; HLA DR3 ANTIGEN; HYDROCORTISONE; INDOMETACIN; LAMIVUDINE; MANNITOL; NORADRENALIN; PARACETAMOL; PENICILLIN G; PROPOFOL; STEROID; TERLIPRESSIN; VASOPRESSIN;

ACID BASE BALANCE; ADRENAL DISEASE; AMMONIA BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BRAIN DISEASE; BRAIN EDEMA; BRAIN LEVEL; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; HEPATITIS B; HUMAN; HYPOGLYCEMIA; IN VIVO STUDY; INTENSIVE CARE UNIT; INTRACRANIAL HYPERTENSION; INTRACRANIAL PRESSURE MONITORING; KIDNEY FAILURE; LIVER FAILURE; LIVER GRAFT; MEAN ARTERIAL PRESSURE; MONOCYTE; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; PATIENT REFERRAL; PROGNOSIS; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; SPLANCHNIC BLOOD FLOW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

BRAIN EDEMA; CEREBROVASCULAR CIRCULATION; HEPATIC ENCEPHALOPATHY; HLA-DR ANTIGENS; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; INTRACRANIAL HYPERTENSION; LIVER FAILURE, ACUTE; PROGNOSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME FACTORS;

EID: 41849110983     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e3282f6a450     Document Type: Review

References (71)

1. Trey C, Lipworth L, Davidson CS. Halothane and liver damage. N Engl J Med 1969; 280:562-563.
2. Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003; 23:217-226.
3. Keays R, Harrison PM, Wendon JA, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ 1991; 303:1026-1029.
4. Harrison PM, Wendon JA, Gimson AE, et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 1991; 324:1852-1857.
5. Lee WM, Rossaro L, Fontana RJ, et al. Intravenous N-acetylcysteine improves spontaneous survival in early stage nonacetaminophen acute liver failure [abstract]. Hepatology 2007; 46 (Suppl 1):268A.
6. Niemi TT, Munsterhjelm E, Pöyhiä R, et al. The effect of N-acetylcysteine on blood coagulation and platelet function in patients undergoing open repair of abdominal aortic aneurysm. Blood Coagul Fibrinolysis 2006; 17:29-34.
7. Heller AR, Groth G, Heller SC, et al. N-acetylcysteine reduces respiratory burst but augments neutrophil phagocytosis in intensive care unit patients. Crit Care Med 2001; 29:272-276.
8. Castro MA, Fassett MJ, Reynolds TB, et al. Reversible peripartum liver failure: a new perspective on the diagnosis, treatment, and cause of acute fatty liver of pregnancy, based on 28 consecutive cases. Am J Obstet Gynecol 1999; 181:389-395.
9. Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13:256-263.
10. Broussard CN, Aggarwal A, Lacey SR, et al. Mushroom poisoning-from diarrhea to liver transplantation. Am J Gastroenterol 2001; 96:3195-3198.
11. Ichai P, Duclos-Vallee JC, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13:996-1003.
12. O'Grady J, Alexander G, Hayllar K, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97:439-445.
13. Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure. Lancet 2002; 359:558-563.
14. Rehm M, Orth V, Scheingraber S, et al. Acid-base changes caused by 5% albumin versus 6% hydroxyethyl starch solution in patients undergoing acute normovolemic hemodilution: a randomized prospective study. Anesthesiology 2000; 93:1174-1183.
15. Fisher NC, Mutimer DJ. Central venous cannulation in patients with liver disease and coagulopathy - a prospective audit. Intensive Care Med 1999; 25:481-485.
16. Rolando N, Wade J, Davalos M, et al. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000; 32:734-739.
17. Vaquero J, Polson J, Chung C, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 2003; 125:755-764.
18. Antoniades CG, Berry PA, Davies ET, et al. Reduced monocyte HLA-DR expression: a novel biomarker of disease severity and outcome in acetaminophen induced acute liver failure. Hepatology 2006; 44:34-43. Important investigation into the prognostic role of HLA-DR expression on monocytes in ALF. The findings of this study support the theory that immune paralysis may be instrumental in the high incidence of sepsis and MOF in this population.
19. Rolando N, Philpott-Howard J, Williams R. Bacterial and fungal infection in acute liver failure. Semin Liver Dis 1996; 16:389-402.
20. De Jonge E, Schultz MJ, Spanjaard L, et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 2003; 362:1011-1016.
21. Rolando N, Gimson A, Wade J, et al. Prospective controlled trial of selective parenteral and enteral antimicrobial regimen in fulminant hepatic failure. Hepatology 1993; 17:196-201.
22. Koeman M, Van der Ven AJ, Hak E, et al. Oral decontamination with chlorhexidine reduces the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 2006; 173:1348-1355.
23. Bleasedale SC, Trick WE, Gonzales IM, et al. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med 2007; 167:2073-2079.
24. Clemmesen JO, Larsen FS, Kondrup J, et al. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 1999; 29:648-653.
25. Tofteng F, Hauerberg J, Hansen BA, et al. Persistent arterial hyperammonemia increases the concentration of glutamine and alanine in the brain and correlates with intracranial pressure in patients with fulminant hepatic failure. J Cereb Blood Flow Metab 2006; 26:21-27. Large single-centre investigation into the predictive role of arterial ammonia for the development of encephalopathy and ICH. Although severely elevated levels were specific for ICH they lacked sensitivity. Other factors were independently associated with ICH such as age and noncerebral organ failure.
26. Bernal W, Hall C, Karvellas CJ, et al. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology 2007; 46:1844-1852. Large single-centre investigation into the predictive role of arterial ammonia for the development of encephalopathy and ICH. Although severely elevated levels were specific for ICH, they lacked sensitivity. Other factors were independently associated with ICH, such as age and noncerebral organ failure.
27. Bhatia V, Singh R, Acharya SK. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut 2006; 55:98-104. Interesting observational study from the Indian subcontinent linking admission ammonia levels with overall outcome.
28. Vaquero J, Chung C, Blei AT. Cerebral blood flow in acute liver failure: a finding in search of a mechanism. Metab Brain Dis 2004; 19:177-194.
29. Wendon JA, Harrison PM, Keays R, Williams R. Cerebral blood flow and metabolism in fulminant liver failure. Hepatology 1994; 19:1407-1413.
30. Aggarwal S, Kramer D, Yonas H, et al. Cerebral hemodynamic and metabolic changes in fulminant hepatic failure: a retrospective study. Hepatology 1994; 19:80-87.
31. 2 reactivity in fulminant hepatic failure. J Cereb Blood Flow Metab 1995; 15:329-335.
32. Jalan R, Pollock A, Shah SH, et al. Liver derived pro-inflammatory cytokines may be important in producing intracranial hypertension in acute liver failure. J Hepatol 2002; 37:536-538.
33. Wright G, Shawcross D, Olde Damink SW, et al. Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension. Metab Brain Dis 2007; 22:375-388.
34. Ranjan P, Mishra AM, Kale R, et al. Cytotoxic edema is responsible for raised intracranial pressure in fulminant hepatic failure: in vivo demonstration using diffusion weighted MRI in human subjects. Metab Brain Dis 2005; 20:181-192.
35. Cremer OL, Moons KG, Bouman EA, et al. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet 2001; 357:117-118.
36. Ellis AJ, Wendon JA, Williams R. Subclinical seizure activity and prophylactic phenytoin infusion in acute liver failure: a controlled clinical trial. Hepatology 2000; 32:536-541.
37. Sperry RT, Bailey PL, Reichmann MV. Fentanyl and sufentanyl increase intracranial pressure in head trauma patients. Anesthesiology 1992; 77:416-420.
38. Shawcross DL, Davies NA, Mookerjee RP, et al. Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. Hepatology 2004; 39:471-475.
39. Eefsen M, Dethloff T, Frederiksen HJ. Comparison of terlipressin and noradrenalin on cerebral perfusion, intracranial pressure and extracellular concentrations of lactate and pyruvate in patients with acute liver failure in need of inotropic support. J Hepatol 2007; 47:381-386. Contrary to a previous investigation the authors found no increase in ICP with the use of the vasopressin analog terlipressin. The increase in CBF was similar during norepinephrine and terlipressin therapy. There was no evidence of increase in cerebral metabolic rate for oxygen on microdialysis.
40. Vaquero J, Fontana RJ, Larson AM, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 2005; 11:1581-1589.
41. Shami VM, Caldwell SH, Hespenheide EE, et al. Recombinant factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003; 9:138-143.
42. Lidofsky SD, Bass NM, Prager MC, et al. Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology 1992; 17:1-7.
43. Davies MH, Mutimer D, Lowes J, et al. Recovery despite impaired cerebral perfusion in fulminant hepatic failure. Lancet 1994; 343:1329-1330.
44. Canalese J, Gimson AES, Davis C, et al. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut 1982; 23:625-629.
45. Murphy N, Auzinger G, Bernal W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology 2004; 39:464-470.
46. Strauss G, Hansen BA, Knudsen GM, Larsen FS. Hyperventilation restores cerebral blood flow autoregulation in patients with acute liver failure. J Hepatol 1998; 28:199-203.
47. Jalan R, Olde Damink SW, Deutz NE, et al. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. Gastroenterology 2004; 127:1338-1346.
48. Bernal W, Auzinger G, Sizer E, et al. Variation in blood ammonia concentration with site of measurement and evidence of brain and muscle uptake in patients with acute liver failure. Liver Int (in press).
49. Tofteng F, Larsen FS. The effect of indomethacin on intracranial pressure, cerebral perfusion, and extracellular lactate and glutamate concentrations in patients with fulminant hepatic failure. J Cereb Blood Flow Metab 2004; 24:798-804.
50. Rozga J, Podesta L, LePage F, et al. Control of cerebral edema by total hepatectomy and extracorporeal liver support in fulminant hepatic failure. Lancet 1993; 342:898-899.
51. Murphy ND, Kodakat SK, Wendon J, et al. Liver and intestinal lactate metabolism in patients with acute liver failure undergoing liver transplantation. Crit Care Med 2001; 29:2111-2118.
52. Pinsky MR, Payen D. Functional hemodynamic monitoring. Crit Care 2005; 9:566-572.
53. Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007; 370:676-684.
54. Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003; 107:2313-2319.
55. Harry RA, Auzinger G, Wendon JA. The clinical importance of adrenal insufficiency in acute hepatic dysfunction. Hepatology 2002; 36:395-402.
56. Parekh NK, Hynan LS, De Lemos J, et al. Elevated troponin I levels in acute liver failure: is myocardial injury an integral part of acute liver failure? Hepatology 2007; 45:1489-1495. Interesting study investigating the role of covert myocardial injury in ALF and its role in relation to outcome.
57. Fuhrmann V, Madl C, Mueller C, et al. Hepatopulmonary syndrome in patients with hypoxic hepatitis. Gastroenterology 2006; 131:69-75. This is the first time that a high incidence of hepatopulmonary syndrome was reported outside the setting of chronic liver disease in a subgroup of patients with ALF. It remains to be seen if some degree of intrapulmonary shunting complicates all forms of ALF.
58. Baudouin SV, Howdle P, O'Grady JG, et al. Acute lung injury in fulminant hepatic failure following paracetamol poisoning. Thorax 1995; 50:399-402.
59. Auzinger G, Sizer E, Bernal W, et al. Incidence of lung injury in acute liver failure: diagnostic role of extravascular lung water index. Crit Care 2004; 8 (Suppl 1):40.
60. Schultz MJ, Haitsma JJ, Slutsky AS, et al. What tidal volumes should be used in patients without acute lung injury? Anesthesiology 2007; 106:1226-1231.
61. Auzinger G, O'Callaghan GP, Bernal W, et al. Percutaneous tracheostomy in patients with severe liver disease and a high incidence of refractory coagulopathy: a prospective trial. Crit Care 2007; 11:R110.
62. Davenport A, Will EJ, Davison AM. Continuous versus intermittent forms of haemofiltration and/or dialysis in the management of acute renal failure in patients with defective cerebral autoregulation at risk of cerebral oedema. Contrib Nephrol 1991; 93:225-233.
63. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356:26-30.
64. Honore PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000; 28:3581-3587.
65. Bernal W, Wong T, Wendon J. High-volume continuous veno-venous haemofiltratiom in hyper-acute liver failure: a pilot study. Crit Care 1999; 3 (Suppl 1):212.
66. Lai YC, Huang HP, Tsai IJ, et al. High-volume continuous venovenous hemofiltration as an effective therapy for acute management of inborn errors of metabolism in young children. Blood Purif 2007; 25:303-308.
67. Kodakat S, Gopal P, Wendon J. Hyperglycemia is associated with intracranial hypertension in patients with acute liver failure. Liver Transpl 2001; 7 (Suppl):C21.
68. Walsh TS, Wigmore SJ, Hopton P, et al. Energy expenditure in acetaminophen-induced fulminant hepatic failure. Crit Care Med 2000; 28:649-654.
69. Schmidt LE, Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology 2002; 36:659-665.
70. Salvino R, Ghanta R, Seidner DL, et al. Liver failure is uncommon in adults receiving long-term parenteral nutrition. JPEN J Parenter Enteral Nutr 2006; 30:202-208.
71. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure. A systematic review. JAMA 2003; 289:217-222.